

---

**NAME: Sumanta (Monty) Pal, MD, FASCO**  
**INSTITUTION: City of Hope**  
**OPEN SEAT: Society Nominating Committee Undesignated Member**

---

**A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION**

**Education:**

1998 M.D. UCLA School of Medicine, Los Angeles, CA  
2003 B.S. California State University, Los Angeles, Los Angeles, CA

**Postdoctoral Training:**

2006-2009 Fellow, Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA  
2004-2006 Resident, Internal Medicine, UCLA Medical Center, Los Angeles, CA  
2003-2004 Intern, Internal Medicine, UCLA Medical Center, Los Angeles, CA

**Licensure and Certification:**

2009, 2019 Oncology, ABIM  
2006-2016 Internal Medicine, ABIM  
2005 California License

---

**B. APPOINTMENTS**

**Academic Appointments:**

2021- Professor, Genitourinary Malignancies, Medical Oncology and Therapeutics Research, City of Hope  
2020-2021 Clinical Professor, Genitourinary Malignancies, Medical Oncology and Therapeutics Research, City of Hope  
2016-2020 Associate Clinical Professor, Genitourinary Malignancies, Medical Oncology and Therapeutics Research, City of Hope  
2009-2016 Assistant Professor, Genitourinary Malignancies, Medical Oncology and Therapeutics Research, City of Hope  
2009- Attending Physician, Department of Medical Oncology, City of Hope

---

**C. SERVICE**

**Service to Institution:**

*Administrative Service*

2022 Member, Promotion Lecture & Ad Hoc Committee Meeting – Rose Li, MD, PhD  
2022 Member, Med Onc New Ways of Working Committee  
2022 Member, Clinical Investigator Training Program  
2021 Member, Promotion Lecture & Ad Hoc Committee Meeting – Leanne Burnham, PhD  
2021- Member, MentorLead Planning Committee  
2021- Member, Clinical Training & Membership Committee  
2021- Member, Cancer Center Leadership Committee

2021 Speaker, Hope Talks, City of Hope Speaker Series  
 2021- Chair, Biospecimen and Data Review Committee (BDRC)  
 2021- Mentor, Medical Oncology Assistant Professors meeting  
 2021 Committee Chair, Promotion Lecture & Ad Hoc Committee meeting – Dr. Marcin Kortylewski  
 2021 Committee Chair, Promotion Lecture & Ad Hoc Committee meeting – Dr. Michael Zourabian  
 2020 Committee Chair, Promotion Lecture & Ad Hoc Committee meeting – Dr. Jana Portnow  
 2020 Member, Hem/Onc Fellowship Applicant Interviews  
 2018- Member, Transformative Leadership Development Program  
 2018- Member, Research & Development and Integrated Steering Committee  
 2016- Disease Team Head, Bladder & Kidney Cancer, City of Hope  
 2016- Member, Executive Committee, City of Hope  
 2014- Member, Cancer Protocol Review & Monitoring Committee (Scientific Review Committee), City of Hope Comprehensive Cancer Center  
 2014- Member, Continuing Medical Education Committee, City of Hope Comprehensive Cancer Center  
 2021-2014 Member, Data Safety & Monitoring Committee, City of Hope Comprehensive Cancer Center  
 2010- Co-Chair, Genitourinary Disease Team, City of Hope  
 2010-2012 Member, Computer Information Systems Super Use, City of Hope Comprehensive Cancer Center  
 2008 Member, City of Hope Clinical Investigator Training Program, City of Hope Comprehensive Cancer Center

### *Teaching Service*

2021 ASCO Oncology Summer Internship (OSI)  
 2020- ASCO Virtual Mentoring Program  
 2019 Graduate School Faculty, Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute

Mentor, Ameish Govindarajan (UCLA/Kern Medical Center, Bakersfield, CA)  
 Mentor: Neal Chawla, MD (Advocate Illinois Masonic Medical Center, Chicago, IL)  
 Mentor: Sabrina Salgia (Mills College Premedical Post Baccalaureate Certificate Program, Oakland, CA)  
 Mentor: Jasnoor Malhotra (University of California, Riverside, Riverside, CA)  
 Mentor: Crystal Favorito (Johns Hopkins University, Baltimore, Maryland)  
 Mentor: Errol Philip, PhD (UCSF School of Medicine, San Francisco, CA)  
 Mentor: Ramya Muddasani (City of Hope, Duarte, CA)  
 Mentor: Alexander Chehrazi-Raffle (City of Hope Hematology/Oncology Fellow, Duarte, CA)  
 ASCO Virtual Mentoring Program: Shuchi Gulati, M.D. (University of Cincinnati)  
 ASCO IDEA Mentor: Manuel Maia, MD (Instituto De Cancer Estado De Sau Paulo, Brazil)  
 International Mentor: Nazli Dizman, MD (Istanbul Medeniyet University, Goztepe Research and Training Hospital, Department of Internal Medicine, Istanbul, Turkey)  
 International Mentor: Paulo Bergerot, MD (UNIFESP Hospital, San Paulo, Brazil)  
 International Mentor: Cristiane Bergerot, Ph.D. (UNIFESP Hospital, San Paulo, Brazil)  
 International Mentor: Manuel Maia Caitano, M.D. (Instituto De Cancer Estado De Sau Paulo, Brazil)  
 International Mentor: Lorena Almeida, Psy.D. (Instituto De Cancer Estado De Sau Paulo, Brazil)  
 International Mentor: Zeynep Zengin, MD (Ankara Yıldırım Beyazıt University, Ankara, Turkey)  
 International Mentor: Luis Meza, MD (Universidad Peruana Cayetano Heredia, Lima, Peru)

### **Service to Profession:**

#### *Professional Organizations*

#### *National/International*

2022 Panelist Member, Presenting Yourself: Being Your Own Best Salesperson, ASCO Trainee & Early Career Advisory Group  
 2022 Member, ACORI Task Force, Association of Community Cancer Centers (ACCC)  
 Ad Hoc Reviewer, SWOG-CTP Executive Review Committee  
 2022 Member, Medical Oncology Association of Southern California (MOASC) Board of Directors  
 2022 Panelist, Shared Decision Making: Understanding your Immunotherapy Choices, KidneyCAN  
 2022 Chair, Disease Focused Clinical Investigators (DFCIs) Genitourinary Malignancies Group, National Cancer Institute (NIH)  
 2021 Member, CoC Quality Integration Committee (QIC) on GU Cancer

2021 Co-Chair, Disease Focused Clinical Investigator (DFCI) Genitourinary Group  
2021 Faculty, Ask the Expert: Clinical Investigators, Provide Perspectives on the Management of Patients with Renal Cell Carcinoma – A Remote Mentoring Initiative, Research to Practice (RTP)

2021 Panelist, OncLive Peer Exchange in treatment options in RCC, OncLive  
2021 Member, NCCN Pfizer Talazoparib Request for Proposal's Development Team (RFPDT), NCCN Oncology Research Program (ORP)

2021 Member, Global Society of Rare Genitourinary Tumors (GSRGT) Leadership Council Meeting  
2020-2019-2019 Member, NCI GUSC Renal Task Force Clinical Trial Planning  
2019 Member, SWOG Digital Engagement Committee  
2018 Member, Annual Meeting News Planning Meeting  
2018 Course Director, ASCO Advantage Program: Renal Cell Carcinoma  
2018 Peer Reviewer, Upcoming 7th Edition on Genitourinary Cancers, ASCO Self-Evaluation Program (ASCO-SEP) Editorial Group

2018 Adjunct Associate Clinical Professor, TGen - Division of Integrated Cancer Genomics  
2018 Member, Society for Immunotherapy of Cancer (SITC) Renal Cell Cancer Immunotherapy Guideline (RC-CIG) Subcommittee

2018 Member, Society of Urologic Oncology-Clinical Trials Consortium (SUO-CTC) Board of Directors

2018 Member, Renal Organ Site Committee - Society of Urologic Oncology-Clinical Trials Consortium (SUO-CTC) Board of Directors

2018 Member, Society for Immunotherapy of Cancer (SITC) – Renal Cell Cancer Immunotherapy Guideline Subcommittee

2017-2019 Committee Chair, Cancer Communications Committee Meeting  
2016 Committee Chair, Kidney Cancer Association Scientific Program  
2016 Member, ASCO Leadership Development Program  
2016 Session Chair, 2016 Cancer Symposium (ASCO/SUO/ASTRO) Timing of Systemic Therapy in Renal Cell Carcinoma

2015-2015-2015 Member, Social Media Working Group, ASCO  
2015 Member, Communications Committee, ASCO  
2015 Committee Chair, Society of Immunotherapy for Cancer (SITC) Patient Meeting  
2015 Session Chair, 2015 ASCO Annual Meeting, Oral Abstract Session for GU Non-Prostate  
2014-2013-2014 Chair, SUO Prostate Cancer Committee SUO  
2013-2014 Member, ASCO Genitourinary Cancers Committee  
2012-2013 Member, ASCO – Her2-Positive Breast Cancer Committee  
2012-2015 Member, Scientific Program Committee (GU Section), ASCO  
2012-2014 Board Member, Clinical Trials Consortium Board of Directors, SUO  
2012 Participant, SWOG Young Investigator Meeting, SWOG  
2010-2009 Member, Bladder Cancer Committee, NCCN  
2009 Participant, SWOG Uro-Oncology New Investigators Course, SWOG  
2006-2006 Member, American Society of Clinical Oncology (ASCO)

### *Editorships*

Associate Editor, Cancer.Net (ASCO), 2019, 2020, 2021  
Associate Editor, Clinical Genitourinary Cancer  
Editorial Board Member, European Urology Oncology

### *Grant Reviews*

2012 Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDRMP) Prostate Cancer Research Program (PCRP) Laboratory-Clinical Transition Scientific Reviewer  
2012 Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDRMP) Prostate Cancer Research Program (PCRP) Clinical & Experimental Therapeutics Scientific Reviewer  
2011 Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDRMP) Prostate Cancer Research Program (PCRP) Laboratory-Clinical Transition Scientific Reviewer  
2010-2011 Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDRMP) Breast Cancer Research Program (BCRP) Scientific Reviewer  
2009-2009 American Medical Association (AMA) Seed Grant Scientific Reviewer

## *Symposia*

2022	Guest Moderator, Management of acoriBladder Cancer, American Urological Association (AUA) Annual Meeting, New Orleans, LA
2022	Moderator, Virtual Challenging Cases in GI/HCC, IntrinsicQ Specialty Solutions
2022	Moderator, CME Medicine Grand Rounds – Radiotherapy for Renal Cell Carcinoma – Renaissance of an Overlooked Approach (Presenter: Shankar Siva, M.D.), City of Hope, Duarte, CA
2022	Chair, Navigating Evolving Standards of Care in Renal Cell Carcinoma: How are Novel Targeted and Immunotherapy Options Impacting Treatment Selection and Sequencing, and What's Next on the Horizon?, PeerView, 2022 Genitourinary Cancers Symposium, San Francisco, CA
2022	Guesterator, Management of Bladder Cancer, Research to Practice, 2022 Genitourinary Cancers Symposium, San Francisco, CA
2021	Chair, PeerView CME RCC symposium IKCS
2021	Moderator, Abstract Oral Presentation and Abstract Rapid Presentation Sessions, Kidney Cancer Research Summit 2021 (KCRS21), Philadelphia, PA
2021	Co-Moderator, Targeted Oncology RCC Case – Based Roundtable, Targeted Oncology
2021	Chair, OncLive State of Science: Genitourinary Cancers
2017	Chair, International Genitourinary Oncology Congress
2017	Chair, OncLive State of Science: Genitourinary Cancers
2015-2017	Chair, Society of Urologic Oncology Prostate Cancer Committee
2016-2018	Chair, Kidney Cancer Association Scientific Program Committee
2015-2016	Chair, Society of Immunotherapy for Cancer (SITC) Patient Meeting

## *Sessions Chaired*

2016	GU Cancers Symposium (ASCO/SUO/ASTRO), Timing of systemic therapy in renal cell carcinoma, San Francisco, CA
2015	ASCO Annual Meeting Oral Abstract Session (GU Non-prostate)

---

## **D. NATIONAL HONORS, SCHOLARSHIPS AND AWARDS**

2021	Fellow of the American Society of Clinical Oncology (FASCO)
2021	City of Hope - 5 Star Rating Patient Satisfaction Awards
2020	City of Hope – Clinical Teaching Award
2020	Los Angeles Business Journal's 2020 "Top Doctors"
2019	European Urology Reviewer of the Month
2018	California State University, Los Angeles – 2018 Distinguished Alumni Award for the College of Natural and Social Sciences
2018	City of Hope - Mentor of the Year Award
2013	11th International Kidney Cancer Association Symposium Young Investigator Award
2012	Southwest Oncology Group Coltman Translational Investigator Award
2011	Tower Cancer Research Foundation Award
2008	ASCO Merit Award, 2008 Breast Cancer Symposium
2009	First Place (Poster Presentation), City of Hope First Annual Collaboration Meeting
2006	Commendation for Excellence in Medical Student Teaching
2005	Outstanding Research Award, American College of Physicians
2003	South Asian Health Association
1998	Phi Kappa Phi Scholarship and Departmental Honors, California State University – Los Angeles

---

## **E. GRANTS/RESEARCH SUPPORT**

### *Active Grants*

June 1, 2019 – June 01, 2022

Progress Charitable Foundation DE

Potential of oligonucleotide therapeutics directed at STAT3 to aid treatment of metastatic kidney cancer

\$66,666.00  
PI

June 1, 2019 – June 01, 2022  
The RD Foundation Inc.  
Potential of oligonucleotide therapeutics directed at STAT3 to aid treatment of metastatic kidney cancer  
\$33,332.00  
PI

September 20, 2019 thru September 28, 2022  
DOD  
Dual-Function CpG-STAT3 Antisense Oligonucleotides for Immunotherapy of Metastatic Prostate Cancer  
\$1,297,500.00  
PI

September 2, 2020 thru September 1, 2025  
DOD (Vanderbilt University)  
The aim of this project is to establish the Academy of Kidney Cancer Investigators (AKCI) framework to ensure continued progress towards the goal of eliminating kidney cancer.  
\$75,082  
Sub PI

*Completed Grants/Research Support  
Funding prior to 2020 available upon request*

April 10, 2019 – April 9, 2022  
Gateway for Cancer Research  
Pilot study to evaluate the biologic effect of CBM588 in combination with nivolumab/ipilimumab for patients with metastatic renal cell carcinoma  
\$144,911.00  
Role: PI

March 31, 2016 – March 30, 2021  
Prostate Cancer Foundation  
Immunotherapy for Metastatic Castration-Resistant Prostate Cancer using CAR-Engineered T cells Targeted Prostate Stem Cell Antigen  
\$300,000/yr  
Co-I

September 1, 2019 thru January 15, 2021  
US DHHS NIH NCI  
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy  
\$68,802.00  
PI

December 30, 2013 – December 31, 2020  
Prostate Cancer Foundation  
Immunotherapy for Prostate Cancer Combining Targeted Inhibition of STAT-3 mediated Immunosuppression with CAR-engineered T Cells.  
\$300,000/yr  
Co-I

---

## F. BIBLIOGRAPHY

Publications (40 most recent first/last author papers; 452 total at <https://tinyurl.com/53xzefzt>)

[1]Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. *Lancet* 2021;397:695–703. [https://doi.org/10.1016/S0140-6736\(21\)00152-5](https://doi.org/10.1016/S0140-6736(21)00152-5).

- [2]Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). *Lancet Oncol* 2022;23:899–909. [https://doi.org/10.1016/S1470-2045\(22\)00278-9](https://doi.org/10.1016/S1470-2045(22)00278-9).
- [3]Pal SK, McGregor B, Suárez C, Tsao C-K, Kelly W, Vaishampayan U, et al. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. *J Clin Oncol* 2021;39:3725–36. <https://doi.org/10.1200/JCO.21.00939>.
- [4]Dizman N, Meza L, Pal SK. Biomarker approach harnessed in trials of personalized medicine for bladder cancer. *Nat Med* 2021;27:761–3. <https://doi.org/10.1038/s41591-021-01300-1>.
- [5]Pal SK, Puente J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, et al. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. *Eur Urol* 2022:S0302-2838(21)02272-7. <https://doi.org/10.1016/j.eururo.2021.12.024>.
- [6]Salgia SK, Govindarajan A, Salgia R, Pal SK. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready? *JCO Precis Oncol* 2021;5:767–70. <https://doi.org/10.1200/PO.21.00078>.
- [7]Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. *J Clin Med* 2020;9:E1508. <https://doi.org/10.3390/jcm9051508>.
- [8]Casuscelli J, Pal SK. Aberrant Splice Variants: A Novel Characterization of Clear Cell Renal Cell Carcinoma. *Eur Urol* 2022:S0302-2838(22)02464-2. <https://doi.org/10.1016/j.eururo.2022.06.013>.
- [9]Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. *Future Oncol* 2022;18:1185–98. <https://doi.org/10.2217/fon-2021-1096>.
- [10]Dizman N, Salgia M, Ali SM, Wu H, Arvanitis L, Chung JH, et al. Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. *Clin Genitourin Cancer* 2020;18:e289–92. <https://doi.org/10.1016/j.clgc.2019.11.020>.
- [11]Bergerot CD, Pal SK. Shining a light on the psychological burden of cancer. *Nat Med* 2022;28:637–8. <https://doi.org/10.1038/s41591-022-01763-w>.
- [12]Dizman N, Arslan ZE, Feng M, Pal SK. Sequencing Therapies for Metastatic Renal Cell Carcinoma. *Urol Clin North Am* 2020;47:305–18. <https://doi.org/10.1016/j.ucl.2020.04.008>.
- [13]Chehrazi-Raffle A, Malhotra J, Salgia S, Favorito C, Hsu J, Wu H, et al. Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses. *JCO Precis Oncol* 2021;5:PO.20.00423. <https://doi.org/10.1200/PO.20.00423>.
- [14]Dizman N, Hsu J, Bergerot PG, Gillece JD, Folkerts M, Reining L, et al. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. *Cancer Med* 2021;10:79–86. <https://doi.org/10.1002/cam4.3569>.
- [15]Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. *J Clin Oncol* 2020;38:1797–806. <https://doi.org/10.1200/JCO.19.03091>.
- [16]Bergerot CD, Liu S, Bergerot P, Pal SK. Quality of Life Data in CheckMate 274: Does It Move the Needle? *Eur Urol Oncol* 2022:S2588-9311(22)00058-X. <https://doi.org/10.1016/j.euo.2022.03.008>.
- [17]Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. *JCO* 2010;28:4877–83. <https://doi.org/10.1200/JCO.2009.26.5983>.

- [18]Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. *BJU Int* 2020;126:73–82. <https://doi.org/10.1111/bju.15058>.
- [19]Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. *Nat Med* 2022;28:704–12. <https://doi.org/10.1038/s41591-022-01694-6>.
- [20]Meza L, Salgia NJ, Patel KC, Pal SK. Learning from BISCAY: The future of biomarker-based trial design in bladder cancer. *Cancer Cell* 2021;39:910–2. <https://doi.org/10.1016/j.ccell.2021.06.011>.
- [21]Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, et al. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. *Cancer* 2020;126:2597–606. <https://doi.org/10.1002/cncr.32806>.
- [22]Zengin ZB, Salgia NJ, Chehrizi-Raffle A, Meza L, Malhotra J, Pal SK. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. *Cancer J* 2020;26:432–40. <https://doi.org/10.1097/PPO.0000000000000473>.
- [23]Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, et al. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. *Eur Urol* 2020;78:916–24. <https://doi.org/10.1016/j.eururo.2020.08.002>.
- [24]Castro DV, Malhotra J, Meza L, Govindarajan A, Philip EJ, Pal SK. How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities. *JACC CardioOncol* 2022;4:271–5. <https://doi.org/10.1016/j.jacc.2022.04.004>.
- [25]Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. *Nat Rev Urol* 2020;17:271–91. <https://doi.org/10.1038/s41585-020-0297-9>.
- [26]Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. *Nat Rev Nephrol* 2020;16:435–51. <https://doi.org/10.1038/s41581-020-0301-x>.
- [27]Sfakianos JP, Gul Z, Shariat SF, Matin SF, Daneshmand S, Plimack E, et al. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. *Eur Urol Oncol* 2021;4:170–9. <https://doi.org/10.1016/j.euo.2020.12.007>.
- [28]Govindarajan A, Castro DV, Zengin ZB, Salgia SK, Patel J, Pal SK. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. *Cancers (Basel)* 2022;14:2049. <https://doi.org/10.3390/cancers14092049>.
- [29]Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, et al. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. *Eur Urol* 2020;78:783–5. <https://doi.org/10.1016/j.eururo.2020.08.007>.
- [30]Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. *Cancer Treat Res Commun* 2020;23:100172. <https://doi.org/10.1016/j.ctarc.2020.100172>.
- [31]Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, et al. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. *JAMA Oncol* 2021;7:1536–43. <https://doi.org/10.1001/jamaoncol.2021.3441>.
- [32]Zengin ZB, Malhotra J, Pal SK. Editorial Comment. *J Urol* 2021;206:251. <https://doi.org/10.1097/JU.0000000000001768.02>.
- [33]Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, et al. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. *Cancer* 2021;127:354–8. <https://doi.org/10.1002/cncr.33238>.
- [34]Meza L, Chawla NS, Giannarini G, Pal SK. Cytoreductive Nephrectomy in 2021: Obsolete. *Eur Urol Open Sci* 2022;36:44–6. <https://doi.org/10.1016/j.euro.2021.09.021>.

[35]Meza L, Chehrazi-Raffle A, Pal SK. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered. *Curr Opin Urol* 2020;30:740–2. <https://doi.org/10.1097/MOU.0000000000000809>.

[36]Dizman N, Lyou Y, Salgia N, Bergerot PG, Hsu J, Enriquez D, et al. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. *J Immunother Cancer* 2020;8:e000953. <https://doi.org/10.1136/jitc-2020-000953>.

[37]Salgia R, Mambetsariev I, Tan T, Schwer A, Pearlstein DP, Chehabi H, et al. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. *J Clin Med* 2020;9:E1884. <https://doi.org/10.3390/jcm9061884>.

[38]Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, et al. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. *Clin Cancer Res* 2021;27:4807–13. <https://doi.org/10.1158/1078-0432.CCR-21-0572>.

[39]Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, et al. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. *J Immunother Cancer* 2021;9:e002009. <https://doi.org/10.1136/jitc-2020-002009>.

[40]Salgia NJ, Chehrazi-Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, et al. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. *Cancer Med* 2021;10:5671–80. <https://doi.org/10.1002/cam4.4119>.